The Prescription Drug Work Group's goal is to reduce prescription drug abuse and overdose in Taos County. The Prescription Drug Work Group works closely with medical professionals, law enforcement, and community members to address this rapidly rising problem.

When: 3rd Thursday of the Month at 12:00 PM 

Where: Holy Cross Hospital Board Room 

Look for meeting dates on our Calendar Page or to get involved email taosalive@gmail.com.

Drug Overdose Map.jpg

For more information about Prescription Drug Abuse visit:
www.prescriptiondrugabuse.org
www.drugabuse.gov
www.justice.gov/dea/concern/prescription_drug_fact_sheet.html
www.cadca.org/resources/detail/rx-abuse-prevention-toolkit

Prescription Drug Pamphlet

Prescription drug abuse awareness pamphlets will be distributed at Taos pharmacies along with medications to educate the public on the rising prescription drug abuse problem.  Click here to view

Prescription Drug Poster

The prescription drug poster will be displayed at doctor's offices and pharmacies warning patients of the dangers of prescription drug abuse.

Permanent Prescription Drop Box Flyer

The permanent prescription drop box is located at Taos Police Department and Questa Police Department and is available for disposal Monday through Friday 8:00 AM to 5:00 PM.  No questions asked.   Please print the flyer and post. 

Taos County Suboxone/Subutex/buprenorphine opioid Treatment Services as of 5/4/2012

A list provided Taos County Department of Health of providers of buprenorphine opiod treatment services in Taos County as of May 4, 2012.  Click here for list

SM 18 NM Drug Policy Task Force Final Report

This is the final report from the SM18 NM Drug Policy Task Force. For those of you who did not receive the Executive Summary it is contained within this report. The recommendations date back to January 2012, the time of the last review of recommendations by the task force. This report also includes substantial up to date research and all of our recommendations. Even though it is quite long, it is designed so that you can focus in on a certain topic without needing to read the rest of the report. The appendices relate to some of the sections but also can also be read as standalone documents. Please feel free to distribute on your list serves and to anyone that would benefit from this information.
Click Here to See Final Report

Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids

On July 9, 2012, FDA approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications.

ER/LA opioids are highly potent drugs that are approved to treat moderate to severe persistent pain for serious and chronic conditions (list of ER/LA opioid products1). The misuse and abuse of these drugs have resulted in a serious public health crisis of addiction, overdose, and death.

The REMS is part of a multi-agency Federal effort to address the growing problem of prescription drug abuse and misuse. The REMS introduces new safety measures to reduce risks and improve safe use of ER/LA opioids while continuing to provide access to these medications for patients in pain

http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm

 

  •  

Initiatives of the Taos Alive Prescription Drug Workgroup

 

 

 

Bernalillo County Opioid Abuse Accountability Summit

Prevention Video

 

Prescribers Clinical Support System for Opioid Therapies online Training  Click Here for Website